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A B S T R A C T
Background
Respiratory distress (RD) can occur in both preterm and term neonates born through normal vaginal delivery or caesarean section
(CS). It accounts for about 30% of neonatal deaths and can occur at any time following birth. Respiratory distress syndrome (RDS),
transient tachypnoea (rapid breathing) of the newborn and persistent pulmonary hypertension (increased blood pressure of pulmonary
vessels) of the newborn are the most frequent clinical presentations of neonatal RD. Prostaglandins are used in routine obstetric practice
to ripen the uterine cervix and to trigger labour, with those of the E series being preferred over others due to the fact that they are more
uteroselective. Administration of prostaglandins to an expectant mother before delivery causes reabsorption of lung fluid from the fetal
lung and promotes surfactant secretion by inducing a catecholamine surge. As a result, significant reduction in neonatal respiratory
morbidity following a CS could be obtained, leading to reduced long-term complications such as bronchopulmonary dysplasia (chronic
lung disease with lung tissue modification) and asthma.
Objectives
The objective of this review was to determine if administration of prostaglandins before CS can improve respiratory outcomes of
newborns.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (30 September 2013). We also searched three clinical
trial registries; ClinicalTrials.gov, the Australian New Zealand Clinical Trials Registry and the WHO Clinical Trials Registry Platform
(ICTRP), for ongoing studies (24 June 2013).
Selection criteria
We included all published and unpublished randomised controlled trials comparing the use of prostaglandins with other treatments
(including placebo) to reduce neonatal respiratory morbidity. Participants were pregnant women with an indication for a CS, and we
compared administration of prostaglandins prior to CS with no treatment, placebo or another treatment.
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Data collection and analysis
Two review authors independently assessed studies for inclusion and assessed trial quality, with the third review author referred to for
settling any disagreements. Two review authors extracted data. Data were checked for accuracy. We used the Cochrane tool for assessing
risk of bias in the included study and contacted the study authors to request additional information where appropriate.
Main results
We found one randomised controlled trial with a low risk of bias which was carried out in a tertiary neonatal care centre in Australia.
The study involved 36 women (18 received intravaginal prostaglandin E 2 gel and 18 received placebo).
There was one case of neonatal respiratory distress in the control group, which the trialist reported as transient tachypnoea of the
newborn (risk ratio (RR) 0.33, 95% confidence interval (CI) 0.01 to 7.68, one study, n = 36).
None of the neonates required mechanical ventilation and the trial authors reported median Apgar scores at one and five minutes as
being similar in both groups.
There were no treatment-related side effects in either group. Noradrenaline concentrations (median values (range)) were reported as
being significantly higher in the cord blood samples of the intervention group compared to the control group.
Authors’ conclusions
Although the trial authors reported a significant increase in catecholamine levels in the intervention group, there was no significant
difference in the respiratory outcomes between intervention and control groups. The quality of evidence was graded as low because
the sample size was small and there were few events. No definite conclusions can thus be drawn on the effects of prostaglandins on
neonatal respiratory outcomes from this review.
P L A I N L A N G U A G E S U M M A R Y
Administration of prostaglandins to pregnant women before caesarean section to prevent breathing difficulties in newborn
babies
Respiratory difficulties in newborn babies are a common complication following birth. They are more frequent with caesarean section
and when the pregnant woman is operated on before labour starts than when she is in labour. Prostaglandins are a group of substances
that have been used successfully to induce labour in pregnant women. They also have the potential to help the lungs of the newborn
to adapt to breathing air after delivery, by removing fluid from the lungs and increasing surfactant secretion. Caesarean sections are
performed more frequently worldwide and it is important to find interventions that improve the newborn’s breathing following this
surgery.
We found one small randomised trial (involving 36 women) that compared prostaglandin E2 intravaginal gel administered before
caesarean section compared with a placebo gel. The information obtained from this study did not permit us to be certain that
prostaglandins improve neonatal breathing following planned caesarean section at term. Only one baby in the placebo group had
respiratory distress assessed as rapid breathing. Further studies have to be carried out in order to find out the impact of prostaglandins
on the newborn lungs after caesarean section.
2Prostaglandins before caesarean section for preventing neonatal respiratory distress (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Prostaglandin E2 versus placebo before caesarean section for prevention of neonatal respiratory distress
Patient or population: pregnant women at term.
Settings: Regional tert iary neonatal care centre.
Intervention: prostaglandin E2 administered per vagina before caesarean sect ion
Control: K-Y jelly as placebo.
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Prostaglandin E2 ad-
ministered before cae-
sarean section
Respiratory distress
Respiratory rate at rest
> 60/ m in and/ or signs
of respiratory distress.
Follow-up: 1 day.
Study population RR 0.33, 95% CI 0.01 to
7.68,
36
(1 study)
⊕⊕©©
low1
83 per 1000 27 per 1000
(0.01 to 637)
Need for mechanical
ventilation
Follow-up: 1 day.
Study population Not est imable 36
(1 study)
⊕⊕©©
low1
There was no neonate
requiring mechanical
vent ilat ion in either
groups
See comment See comment
Moderate
All cause fetal mortal-
ity
Follow-up: 1 day.
Study population Not est imable 36
(1 study)
⊕⊕©©
low1
There was no reported
neonatal death in the
study.
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See comment See comment
Maternal adverse
events
Study population Not est imable 36
(1 study)
⊕⊕©©
low1
There was no maternal
adverse event reported
in the study.See comment See comment
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1 The optimal information size was not met, conf idence intervals were wide and event rates were low.
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B A C K G R O U N D
Respiratory distress (RD) can occur in all newborns irrespective
of gestational age or mode of delivery. It accounts for about 30%
of neonatal deaths (Harrison 2008) and can occur at birth or sev-
eral hours after delivery (Whitsett 2005). Infants born by elective
caesarean section (CS) delivery at term are at increased risk for
developing respiratory disorders, compared with babies delivered
per vagina (Zanardo 2004) or by emergency CS (Hansen 2007),
the relative risk increasing with decreasing gestational age. The
prevalence of deliveries by CS has been steadily increasing world-
wide over the last few years (Tampakoudis 2004). In 2007, 30.9%
of Australian women gave birth by CS, increasing from 21% in
1998 (Laws 2009). Other countries have high rates of CS with
prevalence rates of up to 50% reported in certain regions of Latin
America (Villar 2006). Previous research has highlighted poten-
tial reasons for the increasing CS rate, including maternal request
and associated ethical and litigious issues (Minkoff 2003; Robson
2008), obesity (Poobalan 2009) and increasing maternal age (Bell
2001; Callaway 2005).
Description of the condition
RD in the neonate following CS can present as several clinical
entities including respiratory distress syndrome (RDS), transient
tachypnoea (rapid breathing) of the newborn and persistent pul-
monary hypertension of the newborn. RDS, sometimes called
hyaline membrane disease complicates about 1% of pregnancies
(Whitsett 2005), often occurs after premature delivery (Bland
2008) and is due to quantitative and qualitative abnormalities in
pulmonary surfactant (Whitsett 2005). Transient tachypnoea of
the newborn (TTN), which is characterised by RD with an in-
crease in respiratory rate following delivery, is caused by delayed
reabsorption of lung fluid (Bland 2008; Whitsett 2005) and has
an incidence of approximately 11% (Whitsett 2005). Persistent
pulmonary hypertension of the newborn occurs when there is a
failure to make the transition from high pulmonary vascular resis-
tance (PVR) and low pulmonary blood flow (PBF) characteristic
of the fetus to the relatively low PVR and high PBF of the post-
natal infant (Whitsett 2005).
Description of the intervention
Prostaglandins are used in obstetrics for cervical ripening and in-
duction of labour with good results (Hofmeyr 2003;Witter 1992).
Prostaglandins of the E series are preferred over the F series because
they aremore uteroselective (O’Brien 1995).Themost widely used
prostaglandins are misoprostol (prostaglandin E1) and dinopros-
tone (prostaglandin E2), which are available as oral tablets, vagi-
nal tablets, pessaries or vaginal gels. For the purposes of cervical
ripening and labour induction, prostaglandin E2 starts acting in
10 minutes and results can be observed within 12 hours (Rayburn
1989). Prostaglandins can stimulate surfactant secretion and re-
duce lung fluid by provoking a catecholamine surge but it is un-
clear how early they have to be administered before CS in order
to produce this effect. A randomised controlled trial found an in-
crease in catecholamine levels in fetal blood in the intervention
group compared with the placebo group, when prostaglandin E2
was administered as intravaginal gel 60 minutes before CS (Singh
2004). Prostaglandins are not used in routine medical practice for
the sole purpose of improving fetal respiratory outcomes. How-
ever, studies in animals have shown that when administered before
CS, they accelerate fetal lung maturation and improve respiratory
function after delivery (Zaremba 1997).
How the intervention might work
Decades ago, it was suggested that poor respiratory outcomes in
infants delivered by elective CS may be explained by delayed ab-
sorption of liquid in the lung due to lack of a catecholamine surge
(Faxelius 1983). Studies in animals during spontaneous or oxy-
tocin-induced labour show an association between an increase in
plasma epinephrine and reduced production and increased ab-
sorption of lung liquid. It is known that prostaglandin E2 stim-
ulates production of surfactant in fetal lungs as term approaches
(Torday 1998). Furthermore, the concentration of beta-adrener-
gic receptors in lung tissue is known to increase late in gestation,
which might render the lungs more responsive to the effects of
epinephrine (Bland 2008). Catecholamines thus promote surfac-
tant secretion (Whitsett 2005) and stimulate reabsorption of lung
fluid from the fetal lung (Bland 2008). This catecholamine surge
can be stimulated by administering prostaglandins to the pregnant
woman before delivery (Singh 2004).
Why it is important to do this review
A study evaluating metabolic adaptation in the newborn revealed
that infants delivered per vagina showed high catecholamine lev-
els at birth compared with infants born by CS under epidural or
general anaesthesia (Hägnevik 1984). Prostaglandins can stimu-
late surfactant secretion and reduce lung fluid by provoking a cate-
cholamine surge (Singh 2004) and therefore significantly reducing
neonatal respiratory morbidity following a CS. This could even-
tually reduce long-term complications such as bronchopulmonary
dysplasia (Bland 2008), which results from prolonged ventilation
in severe RDS and asthma, which develops more frequently in
children aged zero to four years with a history of TTN (Whitsett
2005). It is important to collect and summarise evidence of the
use of prostaglandins for improving fetal respiratory outcomes.
O B J E C T I V E S
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To determine if the administration of prostaglandins before cae-
sarean section improves the respiratory outcomes of newborns.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published and unpublished randomised trials and if unavail-
able, quasi-randomised controlled trials comparing the use of
prostaglandins with other treatments (including placebo) to re-
duce neonatal respiratory morbidity.
Types of participants
All pregnant women with an indication for a caesarean section.
Types of interventions
Administration of prostaglandins prior to caesarean section com-
pared with no treatment, placebo or another treatment.
Types of outcome measures
Primary outcomes
1. Incidence of respiratory distress in neonates: respiratory
distress will be considered as defined by the authors.
2. Need for mechanical ventilation of the neonate: this could
be the Ambu resuscitator or endotracheal intubation.
3. Apgar score of newborn: the Apgar score is usually used to
represent the neonate’s ability to initiate and maintain breathing
after birth on a scale from zero to 10. It is measured at the first
and fifth minute of life. Apgar scores less than three indicate
severe respiratory depression and scores from four to six indicate
mild to moderate respiratory depression. There is no respiratory
depression when the scores are from seven to 10 (Apgar 1953;
Harrison 2008).
Secondary outcomes
Maternal outcomes
We included all adverse events reported by the study authors.
Fetal outcomes
1. Catecholamine levels in the neonate.
2. Neonatal arterial oxygen, carbon dioxide partial pressures
and fetal scalp pH measurements.
3. All cause fetal mortality: any death that occurs from the
time the neonate is included in the study.
4. Proportion of neonates requiring admission into an
intensive care unit.
5. Length of stay in neonatal intensive care unit.
6. Long-term complications related to respiratory distress.
7. Any other adverse event reported by the authors.
Search methods for identification of studies
Electronic searches
We contacted the Trials Search Co-ordinator to search the
Cochrane Pregnancy and Childbirth Group’s Trials Register (30
September 2013).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of Embase;
4. handsearches of 30 journals and the proceedings of major
conferences;
5. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE and
Embase, the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current aware-
ness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
In addition, to the search carried out by the Trials Search Co-
ordinator, we searched ClinicalTrials.gov, the Australian New
Zealand Clinical Trials Registry and the WHO Clinical Trials
Registry Platform (ICTRP), for ongoing studies. Last searched 24
June 2013 (see Appendix 1).
We did not apply any language restrictions.
Data collection and analysis
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Selection of studies
Two review authors (NM and LM) independently assessed identi-
fied studies for inclusion. We resolved disagreements through dis-
cussion.
Data extraction and management
We used a pre-designed and tested data extraction form to collect
data from the eligible studies. Data were extracted in duplicate
using the agreed form. We resolved discrepancies through discus-
sion. We entered data into Review Manager software (RevMan
2011) and checked for accuracy. Some information regarding the
only included study was unclear and we attempted to contact au-
thors of the original reports to provide further details but did not
obtain any response from them.
Assessment of risk of bias in included studies
Two review authors (NM, LM) independently assessed risk of bias
for each study using the criteria outlined in theCochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).We resolved
all disagreement by discussion.
(1) Random sequence generation (checking for possible
selection bias)
We described for the single included study the method used to
generate the allocation sequence in sufficient detail to allow an
assessment of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for the single included study the method used to
conceal allocation to interventions prior to assignment and as-
sessed whether intervention allocation could have been foreseen in
advance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for the single included study the methods used, if
any, to blind study participants and personnel from knowledge
of which intervention a participant received. We considered that
studies were at low risk of bias if they were blinded, or if we judged
that the lack of blinding would be unlikely to affect results. We
assessed blinding separately for different outcomes or classes of
outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for the single included study the methods used, if
any, to blind outcome assessors from knowledge of which inter-
vention a participant received. We assessed blinding separately for
different outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for the single included study, and for each outcome
or class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported and the numbers included in the analysis
at each stage (compared with the total randomised participants),
reasons for attrition or exclusion where reported, and whether
missing data were balanced across groups or were related to out-
comes. Where sufficient information was reported, or could be
supplied by the trial authors, we re-included missing data in the
analyses which we undertook.
We assessed the methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation. We intended to consider studies with more
than 20% missing data as high risk of bias);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for the single included study how we investigated
the possibility of selective outcome reporting bias and what we
found.
We assessed the methods as:
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• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
Wedescribed for the single included study any important concerns
we had about other possible sources of bias.
We assessed whether the study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether the study was at
high risk of bias, according to the criteria given in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
With reference to (1) to (6) above, we assessed the likelymagnitude
and direction of the bias and whether we considered it was likely
to impact on the findings. We planned to explore the impact of
the level of bias by undertaking sensitivity analyses - see Sensitivity
analysis.
Assessment of quality of evidence across studies
We assessed the quality of the body of evidence using the Grad-
ing of Recommendations Assessment, Development and Evalua-
tion (GRADE) (Guyatt 2008), defining the quality of evidence
for each outcome as the extent to which one can be confident
that an estimate of effect or association is close to the quantity of
specific interest (Higgins 2011). The quality rating across stud-
ies has four levels: high, moderate, low or very low. Randomised
controlled trials are categorised as high quality but can be down-
graded; similarly, other types of controlled trials and observational
studies are categorised as low quality but can be upgraded. Factors
that decrease the quality of evidence include limitations in design,
indirectness of evidence, unexplained heterogeneity or inconsis-
tency of results, imprecision of results, or high probability of pub-
lication bias. Factors that can increase the quality level of a body
of evidence include having a large magnitude of effect, whether
plausible confounding would reduce a demonstrated effect, and if
there is a dose-response gradient.
Measures of treatment effect
Dichotomous data
We presented our results as summary risk ratio with 95% con-
fidence intervals for dichotomous data. However, there were no
events for some outcomes therefore, we applied a correction of 0.5
in order to calculate the risk ratio.
Continuous data
For continuous data, we intended to use themean difference where
outcomes were measured in the same way between trials and the
standardised mean difference to combine trials that measured the
same outcome, but used different methods. Data obtained from
the single included study did not permit us to do so and we thus
reported medians and interquartile ranges in the text.
Unit of analysis issues
We did not identify any cluster-randomised trials for inclusion in
this review. However, if we identify cluster-randomised trials in
future updates of this review we will include them in the analy-
ses along with individually-randomised trials. We will adjust their
sample sizes using the methods described in the Cochrane Hand-
book using an estimate of the intracluster correlation co-efficient
(ICC) derived from the trial (if possible), from a similar trial or
from a study of a similar population. If we use ICCs from other
sources, we will report this and conduct sensitivity analyses to in-
vestigate the effect of variation in the ICC. If we identify both
cluster-randomised trials and individually-randomised trials, we
plan to synthesise the relevant information. We will consider it
reasonable to combine the results from both if there is little het-
erogeneity between the study designs and the interaction between
the effect of intervention and the choice of randomisation unit is
considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Dealing with missing data
For the single included study, we noted levels of attrition. We
planned to explore the impact of including studies with high levels
of missing data in the overall assessment of treatment effect by
using sensitivity analysis.
For all outcomes, we carried out analyses, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partic-
ipants randomised to each group in the analyses, and all partici-
pants were analysed in the group to which they were allocated, re-
gardless of whether or not they received the allocated intervention.
The denominator for each outcome in each trial was the number
randomised minus any participants whose outcomes were known
to be missing.
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Assessment of heterogeneity
Weplanned to assess statistical heterogeneity in eachmeta-analysis
using the Tau-squared (T²), I² and Chi-squared (X²) statistics,
regarding heterogeneity as substantial if an I² was greater than
30% and either a T² was greater than zero, or there was a low P
value (less than 0.10) in the X² test for heterogeneity. There was
one included study which did not allow for any meta-analysis or
analysis of heterogeneity.
Assessment of reporting biases
In future, updates of this review, if there are 10 or more studies
in the meta-analysis, we will investigate reporting biases (such as
publication bias) using funnel plots. We will assess funnel plot
asymmetry visually. If asymmetry is suggested by a visual assess-
ment, we will perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using Review Manager software
(RevMan 2011). This review contains one included study and
thus, we could not combine data in meta-analysis.
In future updates of this review, we will use fixed-effect meta-
analysis for combining data where it is reasonable to assume that
studies are estimating the same underlying treatment effect: i.e.
where trials are examining the same intervention, and the trials’
populations and methods are judged sufficiently similar. If there
is clinical heterogeneity sufficient to expect that the underlying
treatment effects differ between trials, or if substantial statistical
heterogeneity is detected, we will use random-effects meta-anal-
ysis to produce an overall summary, if an average treatment ef-
fect across trials is considered clinically meaningful. The random-
effects summary will be treated as the average range of possible
treatment effects and we will discuss the clinical implications of
treatment effects differing between trials. If the average treatment
effect is not clinically meaningful, we will not combine trials.
If we use random-effects analyses, the results will be presented as
the average treatment effect with 95% confidence intervals, and
the estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
We did not carry out our prespecified subgroup analyses due to
insufficient data. We plan to carry out the following subgroup
analysis in future updates of this review.
1. Preterm neonates versus term neonates.
2. Emergency CS versus elective CS.
3. Various types of prostaglandins used.
If we identify substantial heterogeneity, we will investigate it us-
ing subgroup analyses and sensitivity analyses. We will consider
whether an overall summary is meaningful and use random-effects
analysis to produce it.
We will assess subgroup differences by interaction tests available
within RevMan (RevMan 2011). We will report the results of
subgroup analyses quoting the χ2 statistic and P value, and the
interaction test I² value.
Sensitivity analysis
Planned sensitivity analysis was not carried out due to insufficient
data. In future updates, sensitivity analysis will be carried out to
explore the effect of trial quality, including studies assessed as hav-
ing adequate controls in place for the prevention of potential bias.
R E S U L T S
Description of studies
Results of the search
The search of theCochrane Pregnancy andChildbirthGroup’sTri-
alsRegister retrieved two reports. After verification,we realised that
these were two reports of the same trial.We did not find any ongo-
ing studies in the following trial registries: ClinicalTrials.gov, the
Australian New Zealand Clinical Trials Registry and the WHO
Clinical Trials Registry Platform (ICTRP) (see: Figure 1).
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Figure 1. Study flow diagram
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Included studies
We included one randomised controlled trial in this review that
compared prostaglandin E2 with placebo (Singh 2004). It was
a randomised placebo-controlled study that was carried out in
a tertiary regional neonatal care centre in Australia. There were
36 participants, 18 in the intervention and 18 in the control
group. Participants were pregnant women at term with an indi-
cation for elective caesarean section (ECS). Excluded from the
study were: pregnancies with known fetal malformation/s or chro-
mosomal aberration, presence of absolute contraindications for
use of prostaglandin E2 vaginal gel, for example, history of ad-
verse reactions to prostaglandin preparations, ECS deliveries be-
fore 38 weeks’ gestation and failure to obtain informed consent.
The study compared 2 mg of prostaglandin E2 gel with placebo
(K-Y jelly) when administered as intravaginal gel 60 minutes prior
to ECS. The aim of the study was to compare catecholamine lev-
els in neonatal cord blood between the prostaglandin E2 group
and the placebo group. Other outcomes assessed included Apgar
score at one and five minutes, neonatal respiratory distress, ad-
mission into a neonatal special care, arterial and venous pH mea-
surements.The study authors used non-parametric tests (Mann-
Whitney-Wilcoxon test and Fisher’s exact test) to compare both
groups. P values were reported.
Baseline characteristics: the baseline characteristics of partici-
pants in the intervention and control groups were similar. These
included the age of the mother, gestational age, Bishop score, par-
ity, previous caesarean section (CS), cervical dilatation, time to de-
livery following prostaglandin administration and type of anaes-
thesia used during the CS.
Excluded studies
There were no excluded studies.
Risk of bias in included studies
We assessed the risk of bias in the included study using the
Cochrane ’Risk of bias’ tool for randomised controlled trials
(Figure 2).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Allocation of participants to receive either the intervention or con-
trol was done using computer-generated random numbers. It was
not specified if block randomisation was used but there were equal
numbers in each arm. The allocation sequence was concealed us-
ing sequentially numbered opaque envelopes.
Blinding
Enrolled participants received an equal volume of prostaglandin
E2 or K-Y jelly as intravaginal gel ensuring adequate blinding of
participants.
Adequate blinding of the primary investigators, as well as themed-
ical teams in charge of the mother and neonate was done. An in-
dependent research assistant was in charge of opening the sealed
envelopes and administering the drug or placebo to the partici-
pants.
Incomplete outcome data
There was one participant in the control group for whom no data
were reported after randomisation.However, this did not represent
any significant differential loss to follow-up.
Selective reporting
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The investigators reported all the outcomes specified in the
manuscript. We were unable to find a publishedmanuscript of the
protocol for this study.
Other potential sources of bias
We did not identify any other potential source of bias.
Effects of interventions
See: Summary of findings for the main comparison
Prostaglandin E2 Administered Before Caesarean Section for
Prevention of Neonatal Respiratory Distress
The included study reported the following outcomes: respiratory
distress, need formechanical ventilation, Apgar score of newborns,
neonatal catecholamine levels, neonatal blood pH, mortality, ad-
mission into an intensive care unit and adverse events. The contin-
uous outcomes were reported as medians and interquartile ranges.
Hence, the data could not be added to the data and analysis tables
and are re-reported from the original trial report. This review had
a number of other prespecified outcomes that were not reported
in the included study: neonatal arterial oxygen, carbon dioxide
partial pressures, length of stay in neonatal intensive care unit, and
long-term complications related to respiratory distress.
Primary outcomes
Incidence of respiratory distress in the neonate
There was one case of neonatal respiratory distress in the con-
trol group which the authors (Singh 2004) reported as transient
tachypnoea of the newborn (risk ratio (RR) 0.33, 95% confidence
interval (CI) 0.01 to 7.68, one study, n = 36 (Analysis 1.1)).
Need for mechanical ventilation of the neonate
None of the neonates required mechanical ventilation.
Apgar score of the newborn
Apgar score was reported at one and five minutes with the median
(interquartile range) score being nine (eight to nine) and 9.5 (nine
to 10) respectively for the intervention group. For the control
group, the scores were nine (nine to nine) at one minute and nine
(nine to nine) at five minutes.
Secondary outcomes
Catecholamine levels in the neonate
Catecholamine levels in the neonate were reported as median val-
ues (interquartile range). Neonatal noradrenaline concentrations
were reported as being significantly higher in the intervention
group with respect to the control group, with measurements of
15.0 ng/L (9.8 to 28.92) and 4.6 ng/L (1.65 to 14.4) respectively
(P = 0.03). The concentrations of adrenaline did not vary signifi-
cantly between groups; 1.6 ng/L (below 0.5 to 3.1) for interven-
tion group and 1.4 ng/L (below 0.5 to 2.75) for placebo group (P
= 0.6).
Neonatal pH measurements
Arterial and venous pH measurements were similar in both inter-
vention and control groups and were reported as median values
(interquartile range). Arterial pH was 7.31 (7.28 to 7.37) for the
intervention group and 7.31 (7.29 to 7.33) for the control group
(P = 0.70). Venous pHmeasurements for intervention and control
groups were 7.36 (7.34 to 7.39) and 7.37 (7.32 to 7.44) respec-
tively (P = 0.89).
All cause fetal mortality
There were no deaths in the study population.
Proportion of neonates requiring admission into intensive
care unit
No neonate was admitted into an intensive care unit.
Any other adverse event reported by the authors
The trialist reported that there were no treatment-related side ef-
fects reported in either group.
D I S C U S S I O N
Summary of main results
There were 36 women in the one included study, 18 received in-
travaginal prostaglandin E 2 gel and 18 received placebo. One
neonate in the control group developed respiratory distress, re-
ported as transient tachypnoea of the newborn by the authors.
None of the neonates required mechanical ventilation and the Ap-
gar scores at one and five minutes where similar in both groups.
Although no admissions to neonatal intensive care occurred, two
neonates in the control group were admitted into special care. No
further information was provided on the reasons for these admis-
sions. Outcomes indicating respiratory status did not differ signif-
icantly between intervention and control groups and there was no
treatment-related side effects. Noradrenaline concentrations were
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significantly higher in the cord blood samples of the intervention
group.
Overall completeness and applicability of
evidence
The only significant difference in outcomes reported was in nora-
drenaline measurements in neonatal cord blood. Although being
a catecholamine, adrenaline measurements did not differ signif-
icantly between groups. The authors related this to the type of
assay used to measure catecholamine concentrations in the study.
Other indicators of neonatal respiratory well-being such as respi-
ratory distress, mechanical ventilation, admission to special care
and blood gas measurements did not differ between groups. The
evidence from this review is drawn from a single small study and
hence, may not be generalisable to other populations of pregnant
women.
Quality of the evidence
We used the Grades of Recommendation, Assessment, Develop-
ment and Evaluation (GRADE) (Guyatt 2008) approach for grad-
ing the quality of evidence in this review (Higgins 2011) . We car-
ried out one comparison: prostaglandin E2 versus placebo before
ECS for improving respiratory outcomes of the newborn at term.
Given that the included study was a randomised controlled trial,
we started at very high-quality evidence and we downgraded by
two points for imprecision. We did not downgrade for risk of bias,
inconsistency, indirectness and publication bias. We determined
that there was low-quality evidence to determine if prostaglandins
administered before caesarean could prevent neonatal respiratory
distress.
Potential biases in the review process
We were able to identify one randomised controlled trial (Singh
2004) using the comprehensive search strategy of the Cochrane
Pregnancy and Childbirth Group which did not use any language
limitations. We went further and searched three clinical trial reg-
istries and did not find any ongoing trials. It is possible, although
unlikely that other trials have been conducted but not published,
evaluating the effects of prostaglandins on neonatal respiratory
outcomes. Other biases were limited by conducting the data ex-
traction and quality assessment in duplicate.
Agreements and disagreements with other
studies or reviews
Studies in animals have demonstrated the effects of catecholamines
on fetal lung adaptation to extra-uterine life (Torday 1998;
Zaremba 1997).We found no reviews, trials or observational stud-
ies in humans involving the use of prostaglandins for the purpose
of improving neonatal respiratory outcomes. As a result, we cannot
compare the results we derived from this review to other studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Although the trial authors reported a significant increase in cate-
cholamine levels in the intervention group, there was no signifi-
cant difference in the respiratory outcomes between intervention
and control groups. No definite conclusions can thus be drawn
on the effects of prostaglandins on neonatal respiratory outcomes
from this review due to the nature of the evidence available.
Implications for research
Caesarean sections are increasingly performed worldwide, leading
to an increase in the number of neonates at risk of respiratory
distress (RD). It is important to develop interventions that pre-
vent neonatal RD and its consequences. The study included in
this review involved only prostaglandin E2 vaginal gel and had a
small sample size, therefore larger studies are required for better
assessment of the impact of this intervention. Furthermore, the
role of prostaglandins in situations such as emergency caesarean
section and preterm neonates has to be defined,as well as the use
of different dose regimens and routes of administration.
A C K N OW L E D G E M E N T S
We acknowledge the assistance of the Centre for the Develop-
ment of Best Practices in Health (CDBPH) and the South African
Cochrane Centre (SACC). This review is written within the scope
of activities of the Effective Health Care Research Consortium
(EHCRC).
The lead author also acknowledges the MSc in Clinical Epidemi-
ology programme, Faculty of Medicine and Health Sciences, Stel-
lenbosch University.
As part of the pre-publication editorial process, this review has
been commented on by three peers (an editor and two referees
who are external to the editorial team), a member of the Pregnancy
and Childbirth Group’s international panel of consumers and the
Group’s Statistical Adviser.
The National Institute for Health Research (NIHR) is the largest
single funder of the Cochrane Pregnancy and Childbirth Group.
The views and opinions expressed therein are those of the authors
and do not necessarily reflect those of the NIHR, NHS or the
Department of Health.
14Prostaglandins before caesarean section for preventing neonatal respiratory distress (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
References to studies included in this review
Singh 2004 {published data only}
Rane A, Patole S, Singh M, Naidoo D, Buttener P.
Intravaginal Prostin gel prior to elective cesarean section
at term to induce catecholamine surge in cord blood - a
randomised, placebo controlled pilot study. Australian and
New Zealand Journal of Obstetrics and Gynaecology 2003;43:
176.
∗ Singh M, Patole S, Rane A, Naidoo D, Buettner P.
Maternal intravaginal prostaglandin e2 gel before elective
caesarean section at term to induce catecholamine surge in
cord blood: randomised, placebo controlled study. Archives
of Disease in Childhood Fetal & Neonatal Edition 2004;89
(2):F131–F135.
Additional references
Apgar 1953
Apgar V. A proposal for a new method of evaluation of the
newborn infant. Current Research Anesthesia 1953;32(4):
260–7.
Bell 2001
Bell JS, Campbell DM, Graham WJ, Penney GC, Ryan
M, Hall MH. Do obstetric complications explain high
caesarean section rates among women over 30?. BMJ 2001;
322:894–5.
Bland 2008
Bland RD, Carlton DP, Jain L. Lung fluid balance during
development and in neonatal lung disease. In: Bancalari
E, Polin RA editor(s). The Newborn Lung: Neonatalogy
Questions and Controversies. 1st Edition. Philadelphia:
Saunders, 2008:141–65.
Callaway 2005
Callaway LK, Lust K, McIntyre HD. Pregnancy outcomes
in women of very advanced maternal age. Australian and
New Zealand Journal of Obstetrics and Gynecology 2005;45:
12–6.
Faxelius 1983
Faxelius G, Hägnevik K, Lagercrantz H, Lundell B, Irestedt
L. Catecholamine surge and lung function after delivery.
Archives of Disease in Childhood 1983;58:262–6.
Guyatt 2008
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y,
Alonso-Coello P, et al. GRADE: an emerging consensus on
rating quality of evidence and strength of recommendations.
BMJ 2008;336(7650):924–6.
Hansen 2007
Hansen A, Wisborg K, Uldbjerg N, Henriksen T. Risk of
respiratory morbidity in term infants delivered by elective
caesarean section: cohort study. BMJ 2007;336:85.
Harrison 2008
Harrison VC. The Newborn Baby. 5th Edition. Cape Town:
Juta & Company Ltd, 2008.
Higgins 2011
Higgins JPT, Green S, editors. Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 [updated
March 2011]. The Cochrane Collaboration, 2011.
Available from www.cochrane-handbook.org.
Hofmeyr 2003
Hofmeyr GJ, Gulmezoglu AM. Vaginal misoprostol for
cervical ripening and induction of labour. Cochrane
Database of Systematic Reviews 2010, Issue 10. [DOI:
10.1002/14651858.CD000941
Hägnevik 1984
Hägnevik K, Faxelius G, Irestedt L, Lagercrantz H,
Lundell B, Persson B. Catecholamine surge and metabolic
adaptation in the newborn after vaginal delivery and
caesarean section. Acta Paediatrica Scandinavica 1984;73
(5):602–9.
Laws 2009
Laws P, Sullivan EA. Australia’s Mothers and Babies 2007.
23. Vol. 17, Sydney: AIHW National Perinatal Statistics
Unit, 2009.
Minkoff 2003
Minkoff H, Chervenak FA. Elective primary caesarean
delivery. New England Journal of Medicine 2003;348:
946–50.
O’Brien 1995
O’Brien WF. The role of prostaglandins in labor and
delivery. Clinics in Perinatology 1995;22(4):973–84.
[PUBMED: 8665768]
Poobalan 2009
Poobalan AS, Aucott LS, Gurung T, Smith WC,
Bhattacharya S. Obesity as an independent risk factor for
elective and emergency caesarean delivery in nulliparous
women-systematic review and meta-analysis of cohort
studies. Obesity Reviews 2009;10:28–35.
Rayburn 1989
Rayburn WF. Prostaglandin E2 gel for cervical ripening
and induction of labor: a critical analysis. American
Journal of Obstetrics and Gynecology 1989;160(3):529–34.
[PUBMED: 2648830]
RevMan 2011 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Version 5.1. Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration,
2011.
Robson 2008
Robson S, Carey A, Mishra R, Dear K. Elective caesarean
delivery at maternal request: a preliminary study of
15Prostaglandins before caesarean section for preventing neonatal respiratory distress (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
motivations influencing women’s decision-making.
Australian and New Zealand Journal of Obstetrics and
Gynaecology 2008;48:415–20.
Tampakoudis 2004
Tampakoudis P, Assimakopoulos E, Grimbizis G, Zafrakas
M, Tampakoudis G, Mantalenakis S, et al. Cesarean section
rates and indications in Greece: data from a 24 year period
in a teaching hospital. Clinical and Experimental Obstetrics
and Gynecology 2004;31:289–92.
Torday 1998
Torday J, Sun H, Qin J. Prostaglandin E2 integrates the
effects of fluid distension and glucocorticoid on lung
maturation. American Journal of Physiology 1998;274:
106–11.
Villar 2006
Villar J, Valladares E, Wojdyla D, Zavaleta N, Carroli G,
Velazco A, et al. Caesarean delivery rates and pregnancy
outcomes: the 2005 WHO global survey on maternal
and perinatal health in Latin America. Lancet 2006;367:
1819–29.
Whitsett 2005
Whitsett JA, Rice WR, Warner BB, Wert SE, Pryhuber
GS. Acute respiratory disorders. In: Macdonald MG,
Mullett MD, Seshia MMK editor(s). Avery’s Neonatalogy:
Pathophysiology and Management of the Newborn. 6th
Edition. Philadelphia: Lippincott Williams & Wilkins,
2005:553–77.
Witter 1992
Witter FR, Rocco LE, Johnson TR. A randomized trial of
prostaglandin E2 in a controlled-release vaginal pessary for
cervical ripening at term. American Journal of Obstetrics and
Gynecology 1992;166(3):830–4.
Zanardo 2004
Zanardo V, Simbi AK, Franzoi M, Solda G, Salvadori A,
Trevisanuto D. Neonatal respiratory morbidity risk and
mode of delivery at term:influence of timing of elective
caesarean delivery. Acta Paediatrica 2004;93:643–7.
Zaremba 1997
Zaremba W, Grunert E, Aurich JE. Prophylaxis of
respiratory distress syndrome in premature calves by
administration of dexamethasone or a prostaglandin F2
alpha analogue to their dams before parturition. American
Journal of Veterinary Research 1997;58:404–7.
References to other published versions of this review
Motaze 2012
Motaze NV, Mbuagbaw L, Young T. Prostaglandins before
caesarean section for preventing neonatal respiratory
distress. Cochrane Database of Systematic Reviews 2012, Issue
9. [DOI: 10.1002/14651858.CD010087
∗ Indicates the major publication for the study
16Prostaglandins before caesarean section for preventing neonatal respiratory distress (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Singh 2004
Methods Randomised placebo controlled trial. The trial was carried out in a regional tertiary
neonatal centre in Australia
Participants Expectant mothers eligible for ECS at 38 weeks’ gestation or more who gave written
consent
The study included 36 women (18 in the intervention group and 18 in the control
group)
Interventions Active: intravaginal administration of 2 mg of prostaglandin E2 gel 60 minutes before
ECS.
Placebo: intravaginal administration of 2 mg of K-Y jelly 60 minutes before ECS
Outcomes The main outcome for the study was adrenaline and noradrenaline levels in neonatal
umbilical cord blood. Measurements of umbilical venous and arterial pH were obtained.
Incidence of neonatal respiratory distress, Apgar score of the newborn, need for mechan-
ical ventilation and proportion of neonates requiring admission into intensive care unit
were also assessed
Notes The ethics committee of the tertiary neonatal care institution where the study was carried
out provided ethics approval
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers.
Allocation concealment (selection bias) Low risk Sealed, coded, opaque, sequentially num-
bered envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Intervention group given prostaglandin E2
gel and control group given an equal vol-
ume of K-Y jelly
Independent research assistant adminis-
tered trial drug or placebo to participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis done, no signif-
icant loss to follow-up
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Singh 2004 (Continued)
Selective reporting (reporting bias) Low risk All expected outcomes of interest to the re-
view reported.
Other bias Low risk No other potential source of bias.
ECS: elective caesarean section
18Prostaglandins before caesarean section for preventing neonatal respiratory distress (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Prostaglandin E2 gel vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Respiratory distress 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Prostaglandin E2 gel vs placebo, Outcome 1 Respiratory distress.
Review: Prostaglandins before caesarean section for preventing neonatal respiratory distress
Comparison: 1 Prostaglandin E2 gel vs placebo
Outcome: 1 Respiratory distress
Study or subgroup Prostaglandin E2 Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Singh 2004 0/18 1/18 0.33 [ 0.01, 7.68 ]
0.01 0.1 1 10 100
Favours Prostaglandin E2 Favours Placebo
A P P E N D I C E S
Appendix 1. Search terms for clinical trial registries
Caesarean, prostaglandin, neonatal respiratory distress. The search combination usedwas (CaesareanANDprostaglandinANDneonatal
respiratory distress)
(Authors wrote and ran this search)
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• South African Cochrane Centre, Medical Research Council, South Africa.
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• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We used the GRADE approach to assess the quality of evidence in this review. Three additional clinical trial registries not reported
in the protocol were searched. We did not find any ongoing studies in the following trial registries: ClinicalTrials.gov, the Australian
New Zealand Clinical Trials Registry and the WHO Clinical Trials Registry Platform (ICTRP).
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Cesarean Section; Preoperative Care [∗methods]; Prostaglandins E [∗administration & dosage]; Randomized Controlled Trials as
Topic; Respiratory Distress Syndrome, Newborn [∗prevention & control]
MeSH check words
Female; Humans; Infant, Newborn; Pregnancy
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